Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 Annual Meeting
- 1 October 2025
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (Suppl 3) , 1-3
Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting was held from July 11 to July 13, 2024, in Seattle, Washington, USA, and was attended by 256 rheumatologists, dermatologists, trainees, patient research partners, patient organization representatives, industry partners, and others. The meeting featured several workshops on various topics including epidemiology, new educational initiatives, use of artificial intelligence for both education and clinical management of disease, use of magnetic resonance imaging in the diagnosis and management of psoriatic disease (PsD), and many more. Young-GRAPPA held a workshop and business meeting about their projects, and many of the young GRAPPiAns contributed as coauthors of the articles in this supplement. Debates focused on whether clinical enthesitis indices reflect true enthesitis and whether they should be discontinued, and whether musculoskeletal symptoms in PsD should be managed by dermatologists or rheumatologists. Here we provide an overview of the features of the GRAPPA 2024 annual meeting and introduce the manuscripts published together in this supplement as a meeting report.Keywords
This publication has 24 references indexed in Scilit:
- How Does Juvenile Idiopathic Arthritis Affect the Work and Usual Activities of Parent Caregivers? The UCAN CAN-DU and CURE International Prospective StudyThe Journal of Rheumatology, 2025
- Emergency Department Visits for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: A Population-Based StudyThe Journal of Rheumatology, 2025
- ACHIEVEMENT OF PROTEINURIA LESS THAN 0.4 G/G IN THE PHASE 3 AURORA 1 STUDY OF VOCLOSPORIN IN LUPUS NEPHRITISThe Journal of Rheumatology, 2025
- DISTINCT MOLECULAR PROFILES OF REMISSION POST-CD19 CAR-T CELL THERAPY VERSUS STANDARD IMMUNOSUPPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUSThe Journal of Rheumatology, 2025
- RELIABILITY OF SLE-DAS, SLEDAI-2K, AND PGA INSTRUMENTS IN ASSESSING SLE DISEASE ACTIVITY: A STUDY AMONG GLOBAL LUPUS EXPERTSThe Journal of Rheumatology, 2025
- The Rheumatologist as the Agent of Change: Utility of Guidelines in the Management of GoutThe Journal of Rheumatology, 2024
- Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE StudiesThe Journal of Rheumatology, 2024
- The Significance of Intracellular Versus Extracellular Calcium Pyrophosphate Crystals in Diagnosing Calcium Pyrophosphate Crystal ArthritisThe Journal of Rheumatology, 2024
- Osteoarthritis Across Joint Sites in the Million Veteran Program Cohort: Insights From Electronic Health Records and Military Service HistoryThe Journal of Rheumatology, 2024
- Genetics of Neonatal Lupus Erythematosus Risk and Specific ManifestationsThe Journal of Rheumatology, 2024